Cardiometabolic Diseases Market Size & Opportunity 2028

The cardiometabolic diseases market is expected to reach US$ 121,804.49 million by 2028 from US$ 93,494.41 million in 2021; it is estimated to grow at a CAGR of 3.9% during 2021–2028.

Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.

Strategic Insights

The cardiometabolic diseases market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosisof CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.

Lucrative Regions in Cardiometabolic Diseases Market

Get more information on this report : Request Free Sample PDF

Market Insights
Increasing Prevalence of Cardiometabolic Diseases

Most cardiovascular diseases can be prevented by addressing behavioral risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As per the International Diabetes Federation (IDF), in 2019, ~463 million adults were living with diabetes, which is expected to reach 700 million by 2045.

There is a global rise in the number of people having one or more CMDs due to increasing smoking, lack of exercise, alcohol consumption, and unhealthy food habits. As per the WHO July 2021 stats, more than 8 million people die every year due to tobacco consumption. Its consumption is higher in low- and middle-income countries, with 80% of its global consumer base living in these countries. The increasing prevalence of obesity is giving rise to the patient base suffering from CMDs as well. With this rapid upswing in the prevalence of CMDs, the need for appropriate cardiometabolic disease treatments has skyrocketed, resulting in tremendous growth of the market.

Type-Based Insights

The cardiometabolic diseases market, by type, is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment held the largest share of the market in 2021, and the segment is anticipated to register the highest CAGR in the market during the forecast period.

Cardiometabolic Diseases Market, by Type – 2021 and 2028

Get more information on this report : Request Free Sample PDF

Treatment-Based Insights

By treatment, the cardiometabolic diseases market is segmented into ACE inhibitors, diuretics, Glucophage, and others. The ACE inhibitors segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR  in the market during the forecast period.

Dosage-Based Insights

The cardiometabolic diseases market, by dosage, is bifurcated into tablet and injection. The tablet segment held a larger market share in 2021 and is anticipated to register a higher CAGR in the market during the forecast period.

Route of Administration-Based Insights

The cardiometabolic diseases market, by route of administration, is bifurcated into oral and intravenous. In 2021, the oral segment held a larger share of the market and is expected to register a higher CAGR in the coming years.

End Users-Based Insights

The cardiometabolic diseases market, by end users, is segmented into clinic, hospital, and homecare setting. In 2021, the hospital segment held the largest share of the market and is anticipated to register the highest CAGR  in the market during the forecast period.

Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the laboratory developed test market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally.

The report segments cardiometabolic diseases market as follows

Based on type, the cardiometabolic diseases market is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others. Based on dosage, the cardiometabolic diseases market is bifurcated into tablet and injection. Based on route of administration, the market is bifurcated into oral and intravenous. Based on end users, the cardiometabolic diseases market is segmented into clinic, hospital, and homecare setting. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Company Profiles

• Eli Lilly and Company
• Bayer AG
• Arrowhead Pharmaceuticals, Inc
• Novartis AG
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• AstraZeneca
• Alnylam Pharmaceuticals, Inc.
• Cardax, Inc
• Kowa Company, Ltd.